Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-770767 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| BMS-770767 ± metformin (Treatment A) | EXPERIMENTAL | - |
| BMS-770767 ± metformin (Treatment B) | EXPERIMENTAL | - |
| BMS-770767 ± metformin (Treatment C) | EXPERIMENTAL | - |
| BMS-770767 ± metformin (Treatment D) | EXPERIMENTAL | - |
| Placebo ± metformin (Treatment E) | PLACEBO_COMPARATOR | - |
| BMS-770767 (Treatment A) | EXPERIMENTAL | - |
| BMS-770767 (Treatment B) | EXPERIMENTAL | - |
| BMS-770767 (Treatment C) | EXPERIMENTAL | - |
| BMS-770767 (Treatment D) | EXPERIMENTAL | - |
| Placebo (Treatment E) | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BMS-770767 | DRUG | Capsule, Oral, 15mg, Active, Daily, 28 days |
| Placebo | DRUG | Capsule, Oral, 0mg, Daily, 28 days |
| Metformin | DRUG | Tablet, Oral, ≥ 1500mg, Active, Daily, 28 days |
Inclusion Criteria: * Diagnosed with type 2 diabetes with inadequate glycemic control and treated with either diet and exercise alone, or with stable doses (≥ 1500mg/d) of metformin for at least 8 weeks prior to screening * HbA1c ≥ 7.0% and ≤ 10.0% with FPG ≤ 240mg/dL (13.3 mmol/dL) Exclusion Crit...
BMS-770767 is an investigational small molecule being developed for Type 2 diabetes and dyslipidemia. It has been studied in Phase 2 clinical trials for these metabolic conditions. The drug is not approved and remains in clinical development.
BMS-770767 is being developed by Bristol-Myers Squibb Company, traded on the New York Stock Exchange under the ticker BMY. The company has conducted clinical trials of this investigational drug for metabolic indications.
BMS-770767 is in Phase 2 clinical development. Two Phase 2 trials have been completed, one in Type 2 diabetes and one in dyslipidemia. The drug is investigational and has not been approved by regulatory authorities.
BMS-770767 has been studied in two completed Phase 2 trials. NCT01046422 evaluated the drug in subjects with Type 2 diabetes, enrolling 76 participants. NCT01058083 evaluated it in subjects with hypercholesterolemia, enrolling 81 participants. Both trials were randomized, double-blind, and placebo-controlled.
BMS-770767 is not FDA approved. It is an investigational drug that has completed Phase 2 clinical trials for Type 2 diabetes and dyslipidemia. The drug remains in clinical development and has not been authorized for marketing.